-
ESMO is unstoppable in the field to hit the ADC, and a new generation is imminent
Time of Update: 2022-10-03
The study showed that ZW49 has a manageable safety profile with encouraging antitumor activity in HER2-positive cancer patients receiving multi-line therapy.
The study showed that ZW49 has a manageable safety profile with encouraging antitumor activity in HER2-positive cancer patients receiving multi-line therapy.
-
NATURE: Atenlimizumab is safe and effective as a neoadjuvant therapy for resectable non-small cell lung cancer
Time of Update: 2022-10-03
Download the Doctor Station App and subscribe anytime, anywhere*For medical professionals only1 minute a day, give you a professional "talking point" in the tumor circle!
Download the Doctor Station App and subscribe anytime, anywhere*For medical professionals only1 minute a day, give you a professional "talking point" in the tumor circle!
-
ESMO Big Coffee Review Professor Xu Songtao: Neo-adjuvant immune combination "doubles" resectable lung cancer pCR! Expect long-term survival outcomes
Time of Update: 2022-10-03
Editor: Xiaoyuan Medical pulse through the collation, unauthorized please do not reprint The European Society for Internal Oncology Annual Meeting (ESMO) is the most prestigious and influential oncolo
-
ESMO Voice of China Prof. Liu Shuku Team/Prof. Long Hao Team: An Exploration of Neoadjuvant Immunotherapy in Early and Local Advanced Lung Cancer
Time of Update: 2022-10-03
Method: This is a single-arm, phase II trial (ChiCTR2100044645) in which eligible patients were 18 to 70 years of age, newborne, histically proven stage IIB-IIIB LUSCs. Enrolling patients received carrelizumab (day 1, 200 mg), albumin paclitaxel (90 mg/m2, days 1 and 8), and carboplatin (AUC 5, day 1) or cisplatin(75 mg/m2, day 1), intravenously, Q3W, treatment for 2-4 cycles, 3-4 weeks after sequential surgery.
-
Histopathological consensus regarding the diagnosis of progressive GBM in adults
Time of Update: 2022-10-03
(Level of evidence: Level III)Question 2: For adult patients with progressive glioblastoma, can repeated testing for MGMT promoter methylation provide new diagnostic and prognostic information beyond the initial tumor information?
-
MRI guided laser interstitial hyperthermia for the treatment of brain stem tumors
Time of Update: 2022-10-03
In a 69-year-old patient with right-sided pontine brain metastases, MRI imaging shows ablation therapy with frontal approach insertion into the cannula.
In a 69-year-old patient with right-sided pontine brain metastases, MRI imaging shows ablation therapy with frontal approach insertion into the cannula.
-
【Cancer Cell】Breakthrough! New Approach Makes KRAS Cancer Genes Say 'Eat Me' to the Immune System
Time of Update: 2022-10-03
In their new work, the research team showed that when ARS1620, a targeted KRAS drug similar to Sotolasi, binds to the mutated KRAS, it not only prevents KRAS from aiding tumor growth, but also induces cells to recognize the ARS1620-KRAS complex as a foreign molecule.
-
ESMO Voice of China | Socazolimab combined chemotherapy as a Chinese group analysis of neoadjuvant therapy for esophageal squamous cell carcinoma
Time of Update: 2022-10-03
Conclusion of the study Although the difference was not statistically significant, neoadjuvant Socazolimab combination chemotherapy showed a numerically advantageous rate of MPR and pCR in patients with locally advanced ESCC and did not increase the incidence of perioperative complications in patients.
-
【2022 ESMO】Breaking the cocoon into a butterfly, born to the new Professor Wang Zhijie: EGFR ex20ins non-small cell lung cancer treatment field adds a new evidence!
Time of Update: 2022-10-03
Among them, the data received by Amivantamab (AMI group) were from the CHRYSALIS study; Data for the RW treatment regimen (external control group) are from the Japanese cohort of EGFR ex20ins mutations in advanced NSCLC who received docetaxel (DOC)/tyrosine kinase inhibitor (TKI)/immunotherapy (IO) for the first time after platinum chemotherapy failure screened by the Asian Lung Cancer Genome Monitoring Platform (LC-SCRUM-Asia).
-
【CEJ】The team of Central South University successfully developed a new anti-tumor immunostimulatory nanodrug
Time of Update: 2022-10-03
This article is the original of the translational medicine network, please indicate the source when reprinting Author: JevinRecently, the School of Life Sciences of Central South University and resear
-
JAMA Oncol (IF=33) Clinical trials by the poolside team of Fujian Medical University have proved that laparoscopic surgery is safer and more effective in the treatment of rectal cancer
Time of Update: 2022-10-03
Postoperative recovery and complications (Figure from JAMA Oncology) Overall, the results of this LASRE randomized clinical trial suggest that laparoscopic surgery for low-grade rectal cancer when performed by an experienced surgeon produces pathological results comparable to open surgery in terms of complete mesenterectomy, negative margins, with higher sphincter retention and good postoperative recovery.
-
ESMO 2022 takes stock of the highlights of early breast cancer
Time of Update: 2022-10-03
brief summaryThe results of many clinical trials of extended therapy after 5 years of AI-assisted endocrine therapy are inconsistent, and GIM4 studies have shown that after 2 to 3 years of amoxifen treatment, adjuvant therapy regimens that extend the use time of letrozole can bring greater benefits to postmenopausal HR+ breast cancer patients; In the NSABP B42 study, the AI treatment group with extended 5 years increased overall DFS by 3.
-
2022 Prof. Hao Wang, ESMO |: After the advancement of the first-line treatment of HR+/HER2-ABC/MBC with fluvixamine monotherapy, pipexicil mPFS was added for up to 9.4 months
Time of Update: 2022-10-03
In the TREnd study, researchers randomized HR+/HER2-advanced patients who had progressed prior to first- and second-line endocrine therapy (fluvixazole or AI monotherapy) and received a pipexil or pipexicil combined with a proendocrine regimen, and the results showed that the mPFS benefit of 6.
-
Cerebellar mutism syndrome
Time of Update: 2022-10-03
In order to promote the diagnosis, prevention and intervention of CMS, Fatema Malbari of the Department of Pediatric Neurology and Developmental Neuroscience, Texas Children's Hospital, Baylor College of Medicine, Houston, USA, provided a comprehensive overview of the etiology, diagnosis, risk factors, clinical manifestations and clinical management of CMS, and identified important multidisciplinary research priorities, the results of which were 。 Results of the studyClinical diagnosis and management: CMS usually occurs 0 to 7 days postoperatively with brief silence.
-
Liposome small molecule mixed nanoparticles are used for fluorescence imaging and treatment of gliomas in vivo
Time of Update: 2022-10-03
of the School of Chemistry and Chemical Engineering of Chongqing Southwest University used mitochondrial membrane potential analysis, electron microscopy and cell ROS level detection, and in vivo/in vitro fluorescence imaging to cultivate glioma cell lines and mouse in situ glioma models in vitro to study the synthetic mitochondria-targeted lipid small molecules-amphiphilic demagnification a-quinolinium conjugate (pheophorbide a-quinolinium conjugate, PQC) Characterization, Targeting, Biosafety, and Therapeutic Efficacy of Mixed Nanoparticles (LPHNPs), published in the June 2022 issue of Acta Pharmaceutica Sinica B.
-
The latest advances in the treatment of solid tumors with mRNA tumor vaccine and CLDN6 CAR-T have a disease control rate of 67%
Time of Update: 2022-10-03
September 19, 2022 / eMedClub News/-Recently, BioNTech announced at ESMO 2022 the latest data on the Phase 1/2 clinical trial of its Claudin-6 (CLDN6)-targeted CAR-T therapy BNT211 for the treatment of patients with recurrent or refractory advanced solid tumors.
-
A novel drug for the treatment of glioblastoma in children
Time of Update: 2022-10-03
Johanna Wyss of the Aarau Children's Oncology Center in Switzerland and others introduced new drugs that can currently be used for GBM in children, and the article was published online in June 2022 in Cancers.
-
【Nature Sub-journal】Zhu Zhenggang of Shanghai Jiao Tong University and other teams published a pangenomic analysis of gastric cancer in China
Time of Update: 2022-10-03
The researchers found that four distribution genes, ACOT1, GSTM1, SIGLEC14, and UGT2B17, exhibited extremely high deletion frequencies in gastric cancer populations.
The researchers found that four distribution genes, ACOT1, GSTM1, SIGLEC14, and UGT2B17, exhibited extremely high deletion frequencies in gastric cancer populations.
-
NSCLC first-line "dechemotherapy" Chinese research shines in 2022 ESMO, opening a new model of "immune +"
Time of Update: 2022-10-03
A SUNRISE study led by Professor Han Baohui of the Chest Hospital of Shanghai Jiao Tong University School of Medicine was selected for oral presentation at ESMO Conference, which is a randomized and controlled study of Xindilizumab combined with alotinib versus amlotinib for the first-line treatment of platinum-containing chemotherapy for metastatic non-small cell lung cancer (NSCLC)[1].
-
ESMO on-site direct attack After the progression of ositinib, ositinib combined treatment "re-challenge", fast response within 6 weeks, ORR exceeded 50%
Time of Update: 2022-10-03
Details are as follows: Professor Julien Mazieres 1 Background There is a lack of optimal treatment options after first-line ositinib therapy with advanced NSCLC of EGFR-sensitive mutations, and there is still a high degree of unmet clinical need.
